Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of April 2025, specifically detailing share repurchases executed on April 2, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific block of share buybacks executed as part of an existing program. No revenue, profit, or cash flow data is provided in this specific document.
- Date of Purchase: April 2, 2025
- Shares Purchased: 819,550 ordinary shares
- Price Range: 1,414.50p (Low) to 1,448.50p (High)
- Volume-Weighted Average Price (VWAP): 1,428.35p
- Trading Venue: London Stock Exchange (XLON)
- Broker: Citigroup Global Markets Limited
- Treasury Share Holdings: 188,756,740 shares (post-transaction)
- Shares in Issue (excluding Treasury): 4,126,464,992
Material Changes and Program Status
The purchase was effected pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, the company has purchased an aggregate of 19,686,437 ordinary shares. The shares purchased on April 2 are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the GSK 2024 Annual Report on Form 20-F (pages 277 to 285).
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program announced on February 24, 2025.
- Confirm the total number of voting rights (4,126,464,992) for disclosure threshold calculations under FCA rules.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the aggregate number of shares purchased under the non-discretionary agreement.